Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
2.

A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.

Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Kenichi Suda, Jiang T, Zhou C, Heasley LE, Hirsch FR.

Clin Lung Cancer. 2018 Sep;19(5):450-456. doi: 10.1016/j.cllc.2018.06.004. Epub 2018 Jun 28.

3.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

PMID:
29885479
4.

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR.

J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.

PMID:
29800747
5.

Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.

Bamberg A, Redente EF, Groshong SD, Tuder RM, Cool CD, Keith RC, Edelman BL, Black BP, Cosgrove GP, Wynes MW, Curran-Everett D, De Langhe S, Ortiz LA, Thorburn A, Riches DWH.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):914-927. doi: 10.1164/rccm.201707-1497OC.

PMID:
29727583
6.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Mol Diagn. 2018 Mar;20(2):129-159. doi: 10.1016/j.jmoldx.2017.11.004. Epub 2018 Jan 23.

PMID:
29398453
7.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.

8.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

Arch Pathol Lab Med. 2018 Mar;142(3):321-346. doi: 10.5858/arpa.2017-0388-CP. Epub 2018 Jan 22. Review.

PMID:
29355391
9.

Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. Review.

10.

Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer.

Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Pivneva I, Borghaei H.

Clin Lung Cancer. 2017 Nov;18(6):640-650.e2. doi: 10.1016/j.cllc.2017.04.010. Epub 2017 Apr 26.

PMID:
28522158
11.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR.

J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.

12.

Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.

13.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

14.

Independent validation test of the vote-counting strategy used to rank biomarkers from published studies.

Rikke BA, Wynes MW, Rozeboom LM, Barón AE, Hirsch FR.

Biomark Med. 2015;9(8):751-61. doi: 10.2217/BMM.15.39. Epub 2015 Jul 30.

15.

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA Jr, Peled N.

Oncologist. 2015 Mar;20(3):316-22. doi: 10.1634/theoncologist.2014-0389. Epub 2015 Feb 26.

16.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.

17.

An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.

Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, Tubbs RR, Hirsch FR.

J Thorac Oncol. 2014 May;9(5):631-8. doi: 10.1097/JTO.0000000000000115.

18.

Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.

Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D.

J Thorac Oncol. 2013 Dec;8(12):1492-501. doi: 10.1097/JTO.0000000000000007.

19.

Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.

Göke F, Göke A, von Mässenhausen A, Franzen A, Sharma R, Kirsten R, Böhm D, Kristiansen G, Stenzinger A, Wynes M, Hirsch FR, Weichert W, Heasley L, Buettner R, Perner S.

Digestion. 2013;88(3):172-81. doi: 10.1159/000355018. Epub 2013 Oct 17.

20.

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, Hirsch FR.

Cell Oncol (Dordr). 2013 Jul;36(4):277-88. doi: 10.1007/s13402-013-0133-9. Epub 2013 Apr 26.

21.

The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.

D'Arcangelo M, Wynes MW, Hirsch FR.

Curr Opin Oncol. 2013 Mar;25(2):121-9. doi: 10.1097/CCO.0b013e32835d8175. Review.

PMID:
23385859
22.

Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.

Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2013 Jan;8(1):19-30. doi: 10.1097/JTO.0b013e31827628ff.

23.

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

Peled N, Palmer G, Hirsch FR, Wynes MW, Ilouze M, Varella-Garcia M, Soussan-Gutman L, Otto GA, Stephens PJ, Ross JS, Cronin MT, Lipson D, Miller VA.

J Thorac Oncol. 2012 Sep;7(9):e14-6. doi: 10.1097/JTO.0b013e3182614ab5. No abstract available.

24.

Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2012 Sep;7(9):1440-8.

25.

The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.

Ekman S, Wynes MW, Hirsch FR.

J Thorac Oncol. 2012 Jun;7(6):947-53. doi: 10.1097/JTO.0b013e31825581bd. Review.

26.

Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.

Wynes MW, Konopa K, Singh S, Reyna-Asuncion B, Ranger-Moore J, Sternau A, Christoph DC, Dziadziuszko R, Jassem J, Hirsch FR.

J Thorac Oncol. 2012 Jun;7(6):982-92. doi: 10.1097/JTO.0b013e31824fe95a.

27.

Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed.

Christoph DC, Hoffmann AC, Gauler TC, Asuncion BR, Loewendick H, Peglow A, Hassan B, Tran C, Wynes MW, Schuler M, Eberhard WE, Hirsch FR.

J Thorac Oncol. 2012 Apr;7(4):766-7. doi: 10.1097/JTO.0b013e3182460fa9. No abstract available.

28.

Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.

Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, Rzyman W, Szostakiewicz B, Jassem J, Hirsch FR.

J Thorac Oncol. 2012 Feb;7(2):340-7. doi: 10.1097/JTO.0b013e318240ca0d.

29.

A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR.

J Thorac Oncol. 2012 Feb;7(2):419-26. doi: 10.1097/JTO.0b013e31823c5b11.

30.

EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.

Mascaux C, Wynes MW, Kato Y, Tran C, Asuncion BR, Zhao JM, Gustavson M, Ranger-Moore J, Gaire F, Matsubayashi J, Nagao T, Yoshida K, Ohira T, Ikeda N, Hirsch FR.

Clin Cancer Res. 2011 Dec 15;17(24):7796-807. doi: 10.1158/1078-0432.CCR-11-0209. Epub 2011 Oct 12.

31.

Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis.

Wynes MW, Edelman BL, Kostyk AG, Edwards MG, Coldren C, Groshong SD, Cosgrove GP, Redente EF, Bamberg A, Brown KK, Reisdorph N, Keith RC, Frankel SK, Riches DW.

J Immunol. 2011 Jul 1;187(1):527-37. doi: 10.4049/jimmunol.1100447. Epub 2011 Jun 1.

32.

Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer.

Badzio A, Wynes MW, Dziadziuszko R, Merrick DT, Pardo M, Rzyman W, Kowalczyk A, Singh S, Ranger-Moore J, Manriquez G, Gaire F, Jassem J, Hirsch FR.

J Thorac Oncol. 2010 Dec;5(12):1905-11. doi: 10.1097/JTO.0b013e3181f38f57.

33.

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.

Salido M, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, Rovira A, Zanui M, Martínez A, Longarón R, Sole F, Serrano S, Bellosillo B, Wynes MW, Albanell J, Hirsch FR, Arriola E.

J Thorac Oncol. 2011 Jan;6(1):21-7. doi: 10.1097/JTO.0b013e3181fb7cd6.

34.

The tissue is the issue: personalized medicine for non-small cell lung cancer.

Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr.

Clin Cancer Res. 2010 Oct 15;16(20):4909-11. doi: 10.1158/1078-0432.CCR-10-2005. Epub 2010 Oct 5.

35.

Early detection and screening of lung cancer.

Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR.

Expert Rev Mol Diagn. 2010 Sep;10(6):799-815. doi: 10.1586/erm.10.60. Review.

PMID:
20843203
36.

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.

Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T, Ikeda N, Hirsch FR.

J Thorac Oncol. 2010 Oct;5(10):1551-8. doi: 10.1097/JTO.0b013e3181e9da60.

37.

Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer.

Peled N, Yoshida K, Wynes MW, Hirsch FR.

Ther Adv Med Oncol. 2009 Nov;1(3):137-44. doi: 10.1177/1758834009347923.

38.

Differential regulation of phagosome maturation in macrophages and dendritic cells mediated by Rho GTPases and ezrin-radixin-moesin (ERM) proteins.

Erwig LP, McPhilips KA, Wynes MW, Ivetic A, Ridley AJ, Henson PM.

Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12825-30. Epub 2006 Aug 14.

39.

Regulation of chemokine expression by NaCl occurs independently of cystic fibrosis transmembrane conductance regulator in macrophages.

Kostyk AG, Dahl KM, Wynes MW, Whittaker LA, Weiss DJ, Loi R, Riches DW.

Am J Pathol. 2006 Jul;169(1):12-20.

40.

TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis.

Frankel SK, Cosgrove GP, Cha SI, Cool CD, Wynes MW, Edelman BL, Brown KK, Riches DW.

Am J Respir Cell Mol Biol. 2006 Mar;34(3):293-304. Epub 2005 Nov 4.

41.
42.

Human insulin-like growth factor-IA expression in transgenic mice promotes adenomatous hyperplasia but not pulmonary fibrosis.

Frankel SK, Moats-Staats BM, Cool CD, Wynes MW, Stiles AD, Riches DW.

Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L805-12. Epub 2004 Dec 23.

43.

IL-4-induced macrophage-derived IGF-I protects myofibroblasts from apoptosis following growth factor withdrawal.

Wynes MW, Frankel SK, Riches DW.

J Leukoc Biol. 2004 Nov;76(5):1019-27. Epub 2004 Aug 17.

PMID:
15316031
44.
45.
46.

Reovirus-induced apoptosis is preceded by increased cellular calpain activity and is blocked by calpain inhibitors.

Debiasi RL, Squier MK, Pike B, Wynes M, Dermody TS, Cohen JJ, Tyler KL.

J Virol. 1999 Jan;73(1):695-701.

47.

Preferential activation of the p46 isoform of JNK/SAPK in mouse macrophages by TNF alpha.

Chan ED, Winston BW, Jarpe MB, Wynes MW, Riches DW.

Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13169-74.

Supplemental Content

Support Center